#ESMO25 最喜爱的研究：CCTG PR21，¹⁷⁷Lu-PSMA-617 对比多西他赛治疗 mCRPC
疗效相似，生活质量差异巨大 (#ESMO26) @DKhalafMD:
✅ FACT-P 在 LuPSMA 上保持稳定，在 Doc 上下降
⚠️ 副作用困扰“相当/非常严重”：15% 对 41%
下一步：经济毒性及治疗后生活质量
163 浏览 · 5 赞 · 3 转发 · 0 回复
BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer
https://esmocongress.esmo.orgAnbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org来源：Kenrick Ng · x.com